Aurobindo Pharma is currently trading at Rs. 706.70, up by 2.20 points or 0.31% from its previous closing of Rs. 704.50 on the BSE.
The scrip opened at Rs. 711.00 and has touched a high and low of Rs. 715.65 and Rs. 702.00 respectively. So far 1,52,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 895.00 on 06-Oct-2016 and a 52 week low of Rs. 504.00 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 725.00 and Rs. 687.50 respectively. The current market cap of the company is Rs. 41,404.00 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 33.81% and 14.32% respectively.
Aurobindo Pharma has received tentative approval from the US Food & Drug Administration (USFDA) under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets, 50mg/300mg/300mg.
The approved product is used for the treatment of HIV-1 infection along as a complete regimen in adults and pediatric patients weighing 40 kg and greater. The reference listed drugs of the approved combination product are ViiV Healthcare’s Tivicay (dolutegravir) and Epivir (Lamivudine), and Gilead Science’s Viread (Tenofovir Disoproxil Fumarate).
ViiV Healthcare and Aurobindo Pharma signed a licensing agreement in 2014 that allows Aurobindo Pharma to supply Dolutegravir 50mg in 92 licensed countries, following completion of required local regulatory approval processes. The triple combination product is expected to be launched in sub-Saharan Africa in Q3FY18.
